Hong Kong Builder Emperor Shares Drop After It Says Debt Overdue
Hong Kong developer Emperor International Holdings Ltd. shares fell the most this year Monday after it reported overdue bank loans and said it's talking to banks on a restructuring plan.
The real estate firm had more than HK$16.6 billion ($2.1 billion) overdue as of March 31 'and/or the Group has breached certain terms of the loan agreements,' according to a filing to the Hong Kong stock exchange late Friday. 'The banks may request immediate repayment of these bank borrowings,' the company said in the filing.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
5 Best Undervalued Stocks To Buy For July 2025
The combination of reasonable valuations, strong competitive positions and clear catalysts for ... More future value recognition makes this group particularly attractive for long-term investors willing to be patient while markets recognize their intrinsic worth. The stock market has always been a realm where patience meets opportunity, and July 2025 presents a particularly compelling landscape for value-oriented investors. While growth stocks continue to dominate headlines, a careful examination of market fundamentals reveals several high-quality companies trading at attractive valuations relative to their intrinsic worth. These opportunities often emerge when market sentiment temporarily overshadows solid business fundamentals, creating windows for astute investors to acquire shares of profitable enterprises at discounted prices. In this comprehensive analysis, we'll explore five exceptional companies that currently trade below their fair value, offering investors the potential for substantial returns as markets eventually recognize their true worth. Each selection represents a different sector and investment thesis, providing diversification opportunities while maintaining a focus on companies with strong competitive positions, healthy balance sheets and clear paths to future growth. These aren't speculative plays or turnaround stories; instead, they are established businesses that have temporarily fallen out of favor with the broader market. How These Undervalued Stocks Were Chosen Selection methodology combines traditional value investing principles with modern financial analysis to identify companies trading below their intrinsic value. The primary screening criteria focused on companies with price-to-earnings ratios significantly below their historical averages and current share prices trading near or below key moving averages, indicating potential technical support levels. I specifically sought companies where the current stock price reflects pessimism that appears disconnected from underlying business performance. Beyond valuation metrics, each selected company demonstrates strong operational fundamentals, including consistent profitability, manageable debt levels and competitive advantages within their respective industries. Businesses with predictable cash flows, experienced management teams and clear catalysts that could drive future value recognition were prioritized. The analysis also considered macroeconomic factors, industry trends and company-specific developments that might influence near-term performance while maintaining focus on long-term value creation potential. 5 Top Undervalued Stocks to Buy In July 2025 1. Johnson & Johnson (JNJ) Johnson & Johnson stands as one of the world's most diversified healthcare conglomerates, operating across three primary segments that have demonstrated remarkable resilience through various economic cycles. The company's pharmaceutical division generates the majority of revenue through innovative treatments in oncology, immunology and infectious diseases, while its medical devices segment serves hospitals and surgical centers globally. The consumer products division, though recently spun off, historically provided stable cash flows through trusted brands like Tylenol, Band-Aid and Neutrogena. Currently trading at approximately $152 per share with a market capitalization of $425 billion, JNJ operates in the healthcare sector, boasting a forward price-to-earnings ratio of 15.8, which is significantly below its five-year average of 18.2. The company maintains an impressive dividend track record, having increased payments for 62 consecutive years, which has earned it Dividend King status. With earnings per share of $10.15 and a robust pipeline of pharmaceutical products in development, Johnson & Johnson presents compelling value characteristics that have attracted long-term investors for decades. Johnson & Johnson's current valuation reflects temporary headwinds rather than fundamental deterioration in its business model. The stock trades near its 200-day moving average of $158, suggesting technical support at current levels, while the pharmaceutical pipeline continues to generate promising clinical trial results. Recent concerns about litigation costs and patent expirations have created selling pressure, but these challenges appear manageable given the company's financial strength and diversified revenue streams. The company's pharmaceutical division continues to launch innovative treatments, with several blockbuster drugs in late-stage development that are expected to drive significant revenue growth over the next five years. Management's focus on high-margin pharmaceutical products, combined with strategic acquisitions and partnerships, positions JNJ to capitalize on demographic trends, including aging populations and increased global healthcare spending. The current dividend yield of 3.2% offers an attractive income while investors await the market's recognition of the company's intrinsic value, making it an ideal core holding for value-oriented portfolios. 2. Berkshire Hathaway (BRK.B) Berkshire Hathaway represents Warren Buffett's masterpiece in value creation, operating as a diversified conglomerate with wholly owned subsidiaries spanning the insurance, energy, manufacturing and retail sectors. The company's insurance operations, including GEICO and Berkshire Hathaway Reinsurance Group, generate substantial float that management deploys into profitable investments and acquisitions. Beyond insurance, Berkshire owns iconic American businesses, including BNSF Railway, Berkshire Hathaway Energy and numerous manufacturing companies that benefit from strong competitive positions and experienced management teams. Trading at approximately $485 per share for Class B shares, Berkshire Hathaway maintains a price-to-earnings ratio of 17.1, which is reasonable for a company of its quality and diversification. The conglomerate generates earnings per share of $22.80 across its various operating segments, though this figure can fluctuate significantly based on investment gains and losses. Unlike most large corporations, Berkshire pays no dividend; instead, it reinvests all profits in growing the business and building shareholder value through capital appreciation and strategic acquisitions. Berkshire Hathaway's current valuation appears attractive relative to the sum of its parts, with the stock trading below its intrinsic value as calculated by many analysts who closely follow the company. The shares recently touched their 50-day moving average of $385, providing a potential entry point for investors seeking exposure to Buffett's investment acumen and the company's diversified business model. Market concerns about succession planning and the advanced age of key leadership have created temporary selling pressure, but these concerns overlook the deep bench of talented managers throughout the organization. The company's massive cash position, currently exceeding $150 billion, provides tremendous flexibility for opportunistic investments and acquisitions during market downturns. Berkshire's operating businesses continue to generate strong cash flows, while the investment portfolio benefits from positions in high-quality companies like Apple, Bank of America and Coca-Cola. The combination of defensive characteristics during economic uncertainty and offensive capabilities during market dislocations makes Berkshire Hathaway an exceptional value proposition for investors seeking long-term wealth preservation and growth. 3. Pfizer Inc. (PFE) Pfizer Inc. operates as one of the world's largest pharmaceutical companies, developing and manufacturing prescription medicines and vaccines that address critical health needs across diverse therapeutic areas. The company's portfolio encompasses treatments for oncology, rare diseases, inflammation and infectious diseases, with a particular strength in areas that require significant research and development investments. Pfizer's recent success with COVID-19 vaccines and treatments has demonstrated its ability to develop and commercialize innovative therapies rapidly. However, this success has also created challenging comparisons as pandemic-related revenues normalize. Currently priced at approximately $24 per share, with a market capitalization of $137 billion, Pfizer trades in the healthcare sector, boasting a forward price-to-earnings ratio of 11.2, which is well below historical averages and those of its peer companies. The stock offers an attractive dividend yield of 5.8%, supported by earnings per share of $2.84 and a commitment to returning capital to shareholders through both dividends and share repurchases. The company's extensive pipeline includes numerous late-stage candidates that could drive future growth, while its established products continue to generate substantial cash flows to fund research and development activities. Pfizer's current valuation reflects excessive pessimism about the company's post-pandemic prospects, creating an attractive entry point for value investors willing to look beyond near-term headwinds. The stock trades near its 52-week low and below its 200-day moving average of $35, suggesting that negative sentiment has been fully reflected in the share price. While COVID-related revenues will inevitably decline, the company's underlying pharmaceutical business remains robust, with several promising drug candidates approaching commercialization that could offset this revenue decline. The pharmaceutical industry's defensive characteristics become particularly valuable during economic uncertainty, as healthcare spending tends to remain stable regardless of broader economic conditions. Pfizer's strong balance sheet, experienced management team, and commitment to innovation position the company to capitalize on demographic trends including aging populations and increased prevalence of chronic diseases. The generous dividend yield offers an attractive income while investors await the market's recognition of Pfizer's diversified pharmaceutical portfolio and promising pipeline developments. 4. Intel Corporation (INTC) Intel Corporation is a pioneer in the semiconductor industry, designing and manufacturing microprocessors and related technologies that power personal computers, data centers and emerging applications, including artificial intelligence and autonomous vehicles. The company's dominant position in central processing units has faced increased competition in recent years, particularly from Advanced Micro Devices and companies developing ARM-based processors, forcing Intel to invest heavily in manufacturing capabilities and product development. Despite these challenges, Intel maintains significant competitive advantages, including advanced manufacturing processes, extensive intellectual property portfolios and long-standing relationships with major technology companies. Trading at approximately $22 per share with a market capitalization of $195 billion, Intel operates in the technology sector, boasting a forward price-to-earnings ratio of 9.8, which represents a significant discount to its historical valuations and those of many of its technology peers. The company generates earnings per share of $4.92 while maintaining a dividend yield of 2.1%, demonstrating management's confidence in future cash flow generation. Intel's substantial investments in new manufacturing facilities and research and development activities position the company to compete effectively in next-generation semiconductor technologies. However, these investments have put pressure on near-term profitability. Intel's current valuation appears to reflect worst-case scenarios regarding the company's competitive position, creating potential upside for investors willing to bet on the company's turnaround efforts. The stock trades below its 200-day moving average of $46, indicating technical weakness that may have created an attractive entry point for long-term investors. Recent management changes and strategic initiatives, including significant investments in manufacturing capacity and partnerships with government entities, indicate that Intel is taking the necessary steps to address competitive challenges and capitalize on the growing demand for semiconductors. The global semiconductor shortage and increasing digitization trends support long-term demand for Intel's products, while government initiatives to strengthen domestic semiconductor manufacturing provide additional tailwinds. Intel's foundry services business represents a significant growth opportunity as companies seek alternatives to Asian manufacturing, particularly given geopolitical tensions and supply chain concerns. The combination of an attractive valuation, a defensive dividend yield and potential catalysts from new product launches and manufacturing investments makes Intel a compelling value proposition for patient investors willing to wait for the company's strategic initiatives to yield results. 5. Coca-Cola Company (KO) The Coca-Cola Company operates as the world's largest beverage company, manufacturing and distributing non-alcoholic beverages across more than 200 countries and territories through an extensive network of bottling partners and distributors. The company's portfolio includes iconic brands such as Coca-Cola, Sprite, Fanta and Dasani, as well as newer additions in categories including energy drinks, sports beverages and premium waters. Coca-Cola's business model focuses on concentrate production and brand marketing, while bottling partners handle manufacturing and distribution, creating an asset-light structure that generates attractive returns on invested capital. Currently valued at approximately $69 per share with a market capitalization of $300 billion, Coca-Cola operates in the consumer staples sector with a forward price-to-earnings ratio of 28.2, which is reasonable for a company with such strong brand recognition and global reach. The stock yields $2.69 per share and offers a dividend yield of 2.9%, supported by 62 consecutive years of dividend increases that have made Coca-Cola a favorite among income-focused investors. The company's global presence and diverse product portfolio provide natural hedges against regional economic fluctuations and changing consumer preferences. Coca-Cola's current trading level near $69 represents attractive value for a company with such enduring competitive advantages and predictable cash flows. The stock recently found support at its 100-day moving average of $63, suggesting technical strength despite broader market volatility. While concerns about health consciousness and sugar consumption have pressured beverage companies, Coca-Cola has successfully diversified its portfolio to include low-calorie and no-calorie options that address changing consumer preferences without sacrificing brand loyalty or pricing power. The company's global footprint presents significant opportunities for growth in emerging markets, where rising incomes and urbanization are driving increased demand for beverages. Coca-Cola's unmatched distribution network and brand recognition create substantial barriers to entry, protecting its market share and pricing power across diverse geographic markets. The reliable dividend growth history, combined with the company's ability to generate consistent cash flows regardless of economic conditions, makes Coca-Cola an ideal core holding for investors seeking stability and income in uncertain market environments. Bottom Line These five undervalued stocks represent compelling opportunities for investors seeking quality companies at attractive prices in July 2025. Each selection offers a different risk-reward profile and sector exposure, ranging from Johnson & Johnson's healthcare stability to Intel's technology turnaround potential. The combination of reasonable valuations, strong competitive positions and clear catalysts for future value recognition makes this group particularly attractive for long-term investors willing to be patient while markets recognize their intrinsic worth. While short-term volatility remains possible, the fundamental strength of these businesses, combined with their current attractive valuations, suggests significant upside potential for investors who can maintain a long-term perspective.
Motor 1
an hour ago
- Motor 1
'Huge Demand:' BMW Is Increasing M2 CS Production Just to Keep Up
BMW's latest M cars are hot commodities. Demand for the M5 is surpassing the automaker's expectations, and now we have word that buyers are placing orders for the new M2 CS in greater numbers than initially predicted. This is forcing BMW to increase the number of build slots in certain markets, including in the United States. Sylvia Neubauer, BMW M's Vice President of Customer, Brand, and Sales, told BMW Blog there's "huge demand" for the new M2 variant. We don't know how many CSs BMW plans to produce or how many each market will receive, but Neubauer said that it has had to increase allotment by "quite some units." Demand is also up in Germany and China. Photo by: BMW The 2026 M2 CS is one of BMW's hottest M cars ever. Under the hood is the brand's twin-turbocharged 3.0-liter straight-six engine producing 523 horsepower and 479 pound-feet of torque. That's 50 more hp and an extra 36 lb-ft of torque over the standard M2 with the eight-speed automatic, which is the only gearbox available in the CS. However, it is rear-wheel drive, unlike BMW's other CS models. The M2 CS is also lighter than the regular M2, primarily due to its carbon-fiber body, with BMW claiming it weighs 97 pounds less. However, it still weighs in at nearly 3,800 pounds. It can reach 60 miles per hour in 3.7 seconds and hit a top speed of up to 188 mph, but all that performance commands a steep price. The 2026 M2 CS starts at $99,775 before any options, and people are lining up to pay six figures for BMW's chunky coupe. If you want one, be prepared to stave off some competition. Supply and Demand: BMW Has a 'Higher Demand' for the M5 Wagon in the US The BMW M5 Wagon Is Already Getting More Expensive Get the best news, reviews, columns, and more delivered straight to your inbox, daily. back Sign up For more information, read our Privacy Policy and Terms of Use . Source: BMW Blog Share this Story Facebook X LinkedIn Flipboard Reddit WhatsApp E-Mail Got a tip for us? Email: tips@ Join the conversation ( )
Bloomberg
an hour ago
- Bloomberg
Trump Threatens to Impose Tariff on Japan, Citing Rice Exports
President Donald Trump threatened to impose a fresh tariff level on Japan, citing what he said was the country's unwillingness to accept rice exports from the US. 'They won't take our RICE, and yet they have a massive rice shortage,' Trump posted Monday on social media. 'In other words, we'll just be sending them a letter, and we love having them as a Trading Partner for many years to come.'
